A method for the manufacture of dabigatran of formula VIII, in which the product of a reaction of 4-ethylamino-3-nitrobenzoic acid chloride with ethyl-3-(pyridin-2- ylamino)propanoate, is converted to the hydrochloride using a hydrogen chloride solution producing the compound of formula III-HC1, in which the nitro group is reduced by means of a reaction with sodium dithionite, and the resulting compound of formula IV is subjected to a reaction with [(4-cyanophenyl)amino] acetic acid and oxalic acid, the product of this reaction Vl-oxal is then subjected to hydrolysis and a reaction with ammonium carbonate to produce the intermediate of formula VII-HCl, which is then converted to dabigatran by means of a reaction with hexyl chloroformate.
一种制备
化学式VIII的
达比加群的方法,其中通过
4-乙基氨基-3-硝基苯甲酸氯化物与乙基-
3-(吡啶-2-基氨基)丙酸乙酯反应生成的产物,使用
氯化氢溶液转化为盐酸盐化合物III-HCl,其中硝基团通过与
亚硫酸钠反应还原,生成的化合物IV经过与[(4-
氰基苯基)
氨基]
乙酸和
草酸反应,得到的产物VI-
草酸盐经过
水解和与
碳酸铵反应,生成
化学式VII-HCl的中间体,然后通过与己基
氯甲酸酯反应将其转化为
达比加群。